-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
There is growing evidence of overactivation of the immune response in patients with severe COVID-19, and several studies have explored the therapeutic effects of immunomodulation on COVID-19.
recently, researchers evaluated the effectiveness of specific lynx inhibitors for COVID-19 treatment through systematic evaluation and meta-analysis in a research paper published in Thorax, an authoritative journal in the field of chest disease.
researchers searched the electronic database until January 7, 2021 to determine the use of immunomodulation agents (anakinra, sarilumab, siltuximab, and tocilizumab) for COVID-19 therapy.
the severity of the disease and the number of days of discharge were measured on a sequentdined scale on the 15th day after the study's main outcome intervention.
key secondary outcomes of the study included overall mortality.
the analysis included 71 studies in a total of 22,058 patients, 6 of which were randomized.
most studies have looked at the prognosis (60/71) of patients treated with tocilizumab.
In prospective studies, tocilizumab was associated with an unanstressed improvement in lifetime (risk ratio of 0.83, 95% CI of 0.72-0.96, I2 of 0.0%) but was not found to be beneficial to other outcomes.
in retrospective studies, the lighter prognossivity measured by tocilizumab and the sequentium scale (overall OR is 1.34, 95% CI is 1.10 to 1.64, I2 is 98%) and adjusted risk of death (HR is 0.52, 95% CI is 0.41 to 0.66, I2 is 76.6%).
difference in hospital stay was 0.36 days (95% CI -0.07 to 0.80, I2 x 93.8%).
that retrospective studies have great heterogeneity, estimates should be interpreted with caution.
other immunomodulants are similar in efficacy to tocilizumab, but the data are insufficient for meta-analysis.
result, the tocilizumab treatment in the prospective study was associated with lower mortality, but other outcomes were inconclusive.
there is no evidence of the efficacy of anakinra, sarilumab or siltuximab in COVID-19 therapy.
